and vaginal atrophy associated with menopause. Clinical data on breast cancer are not available, but both in vitro and in vivo data suggest that ospemifene may have chemopreventive activity in breast tissue.

Bazedoxifene is used for treatment of osteoporosis in postmenopausal women at increased risk of fracture. It has been shown to be relatively safe and well-tolerated. It shows